CheckMate 142: 5-Yr Follow-up With Nivolumab ± Ipilimumab for MSI-H/dMMR Metastatic CRC

From ASCO GI 2023, preliminary safety and efficacy data from the LEAP-015 study of pembrolizumab + lenvatinib + CT for gastroesophageal cancer, as reported by Clinical Care Options (CCO)

Data from ASCO GI 2023 from the SPOTLIGHT trial of zolbetuximab + mFOLFOX6 for CLDN18.2-positive/HER2-negative gastric cancers, as reported by Clinical Care Options (CCO)

Experts highlight key studies being presented at the upcoming 2023 ASCO GI annual meeting in this commentary from Clinical Care Options (CCO)

Christopher H. Lieu, MD Rachna Shroff, MD, MS Released: January 19, 2023

In slides from Clinical Care Options (CCO), experts provide perspectives on updates in biomarker testing and targeted therapy across GI cancers

John L. Marshall, MD
Program Director Christopher H. Lieu, MD Manish A. Shah, MD Released: January 19, 2023